Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Malignant Neoplasm
75%
Biological Marker
73%
Overall Survival
62%
Chemotherapy
55%
Castration Resistant Prostate Cancer
55%
Prostate Cancer
50%
Rectum Cancer
47%
Prednisone
40%
Pazopanib
37%
Renal Cell Carcinoma
37%
Abiraterone Acetate
35%
Progression Free Survival
34%
Chemoradiation Therapy
31%
Androgen
26%
Sunitinib
25%
Androgen Receptor
24%
Colon Carcinoma
23%
Pharmacokinetics
17%
Clinical Trial
16%
Placebo
16%
Immunotherapy
16%
Diseases
16%
Kidney Metastasis
15%
Adverse Event
14%
Enzalutamide
12%
Metastasis
12%
Breast Cancer
12%
Colorectal Carcinoma
12%
Cancer Survival
12%
Thyroid Cancer
11%
Death Receptor
11%
Thyroid Papillary Carcinoma
11%
Secretory Phospholipase A2
11%
Osimertinib
11%
Anaplastic Thyroid Carcinoma
11%
Phospholipase A2
11%
Tigilanol Tiglate
11%
Glioblastoma
11%
Disease Free Survival
11%
Yttrium 90
11%
Polymersome
11%
Patient History of Chemotherapy
11%
Isoflavone
11%
Erlotinib
11%
Micelle
11%
Modafinil
11%
Uterine Cervix Cancer
11%
Chelating Agent
11%
Copolymer
11%
Medicine and Dentistry
Circulating Tumor Cell
98%
Neoplasm
62%
Biological Marker
57%
Colorectal Carcinoma
44%
Malignant Neoplasm
37%
Rectum Cancer
35%
Liquid Biopsy
30%
Disease Free Survival
29%
Cancer Surgery
25%
Clear Cell Renal Cell Carcinoma
23%
Androgen Receptor
23%
Polo Like Kinase 1
23%
Melanoma Cell
23%
Radiation Therapy
23%
Metastatic Carcinoma
20%
Breast Cancer
17%
Clinician
17%
Overall Survival
17%
Nucleic Acid
15%
Disease
14%
Cancer
14%
Mesenchymal-Epithelial Transition
14%
Immunotherapy
14%
Epidermolysis Bullosa Dystrophica
13%
Cancer Cell
13%
Personalized Medicine
13%
Prostate Cancer
12%
Ataxia Telangiectasia
11%
Osimertinib
11%
Gene Frequency
11%
Glioblastoma
11%
Death Receptor
11%
Nutrition Assessment
11%
Lymphocyte Subpopulation
11%
Cell Free Nucleic Acid
11%
Metastatic Colorectal Cancer
11%
Sarcomatoid
11%
Lung Cancer
11%
Immune Checkpoint Inhibitor
11%
Anaplastic Thyroid Carcinoma
11%
DNA Extraction
11%
Tyrosine-Kinase Inhibitor
11%
Exosome
11%
Cancer Survival
11%
Melanoma Cell Line
11%
Proliferating Cell Nuclear Antigen
11%
Yttrium 90
11%
Selective Internal Radiation Therapy
11%
Prospective Cohort Study
11%
Cancer-Related Fatigue
11%
Biochemistry, Genetics and Molecular Biology
Mesenchymal-Epithelial Transition
39%
Androgen Receptor
35%
Disease Free Survival
26%
Overall Survival
24%
Blood Plasma
23%
Epidermal Growth Factor Receptor
23%
Cancer Cell
15%
Droplet Digital Polymerase Chain Reaction
13%
Nucleic Acid
13%
Gene Expression
12%
Cancer Survival
12%
Gene Frequency
11%
Polo-Like Kinase 1
11%
Neutrophil-To-Lymphocyte Ratio
11%
RAD52
11%
CD8
11%
Marker Gene
11%
RNA
11%
Cell Death
11%
Next Generation Sequencing
11%
DNA Extraction
11%
Pembrolizumab
11%
Sensitive Detection
11%
MicroRNA
11%
Genomics
11%
Tumor Volume
11%
Genetic Divergence
11%
Colon
11%
G2 Phase
11%
Proliferating Cell Nuclear Antigen
11%
Transcription
11%
Histone
11%
Gemcitabine
11%
Pazopanib
11%
Lapatinib
11%
DNA Repair Protein
8%
CDKN1B
7%
Epigallocatechin Gallate
7%
IDH1
7%
Long Term Survival
5%
Malignant Transformation
5%
Neutrophil Count
5%
Suxamethonium Chloride
5%
Platelet Count
5%
Epithelial Cell Adhesion Molecule
5%
Cell Cycle
5%
HIF1A
5%